Overview
Michael Gurbisz practices in Vienna, Austria. Mr. Gurbisz is rated as a Distinguished expert by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Chronic Myelomonocytic Leukemia (CMML), Mast Cell Activation Syndrome (MCAS), Leukemia, and Systemic Mastocytosis.
His clinical research consists of co-authoring 12 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Chronic Myelomonocytic Leukemia (CMML).
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chronic Myelomonocytic Leukemia (CMML)Mr. Gurbisz isDistinguished. Learn about Chronic Myelomonocytic Leukemia (CMML).
- Advanced
- Mast Cell Activation Syndrome (MCAS)
- Experienced
- Essential ThrombocythemiaMr. Gurbisz isExperienced. Learn about Essential Thrombocythemia.
- LeukemiaMr. Gurbisz isExperienced. Learn about Leukemia.
- Systemic MastocytosisMr. Gurbisz isExperienced. Learn about Systemic Mastocytosis.